Lantern Pharma Strengthens Board with Appointment of Dr. Lee T. Schalop to Advance AI-Driven Oncology Research
Lantern Pharma enhances its AI-driven precision oncology efforts by appointing Dr. Lee T. Schalop, a seasoned biotech leader, to its Board of Directors.
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company at the forefront of using artificial intelligence (AI) and genomic data to revolutionize oncology drug discovery, has announced the addition of Dr. Lee T. Schalop to its Board of Directors. Dr. Schalop, renowned for his leadership in biotechnology and his expertise in developing targeted therapies for solid tumors, including HK327M-mutant gliomas, brings over two decades of experience to Lantern Pharma. His previous role as co-founder and CEO of Oncoceutics Inc., which was acquired by Chimerix Inc. (NASDAQ: CMRX) and later by Jazz Pharmaceuticals, underscores his significant contributions to the field.
Panna Sharma, CEO of Lantern Pharma, highlighted the strategic value of Dr. Schalop's appointment, noting his deep expertise in neurooncology and his successful track record in strategic transactions. This expertise is expected to complement Lantern's AI-powered drug development platform and its CNS cancer pipeline at Starlight Therapeutics, a subsidiary. Dr. Schalop expressed his enthusiasm for joining Lantern Pharma, emphasizing his commitment to accelerating the company's precision oncology programs to develop novel therapies for patients with limited treatment options.
Lantern Pharma's innovative approach leverages its proprietary AI and machine learning platform, RADR(R), which utilizes over 200 billion oncology-focused data points and a library of more than 200 advanced ML algorithms. This technology has enabled the company to significantly reduce the time and cost associated with bringing new oncology therapies from initial AI insights to first-in-human clinical trials, achieving this in just 2-3 years at approximately $2.5 million per program. The appointment of Dr. Schalop is a strategic move to further enhance Lantern Pharma's capabilities in AI-driven drug discovery and development, positioning the company as a leader in the fight against cancer.